I’m Diane Brady. From transformative weight loss treatment to a potential blockbuster for Alzheimer's, Dave Ricks of Eli ...

We recently published a list of 10 Best Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to ...

Nevertheless, the company's lead obesity candidate ... Adam Spatacco has positions in Eli Lilly. The Motley Fool has no ...

It's shaping up to be a tough period for Eli Lilly and Company , which a week ago released some disappointing third-quarter ...

Eli Lilly (LLY) has been one of the most searched ... While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2024 investor ...

Conditions are getting a bit more challenging for the drugmaker.

Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...

Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Eli Lilly executives insisted that underlying demand for the medicines remained strong and that the company has enough supply available. During an earnings call Wednesday, Eli Lilly instead blamed ...

Eli Lilly executives insisted that underlying demand for the medicines remained strong and that the company has enough supply available. The reason for the disappointing sales, according to the ...